A veteran oncology startup crew is making a very serious bet that they’ve found the key to unlocking the promise of oncolytic viruses
Five years ago, when Amgen ushered the oncolytic virus T-Vec over the finish line at the FDA, 2 things seemed completely clear in short order.
One was that an important new avenue in cancer therapy had been opened up, finding a clean shot at solid tumors while recruiting an immune system attack to “mop up” cancer cell survivors. The other was that any of a number of upstart rivals following that path could do a lot better.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.